FDA Approves Merck ’s Keytruda (pembrolizumab) for Use at an Additional Recommended Dose of 400 mg Every Six Weeks for All Approved Adult Indications

KENILWORTH, N.J.--(BUSINESS WIRE) April 28, 2020 --Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an additional recommended dosage of 400 mg every...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news